JP2019510733A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019510733A5 JP2019510733A5 JP2018530560A JP2018530560A JP2019510733A5 JP 2019510733 A5 JP2019510733 A5 JP 2019510733A5 JP 2018530560 A JP2018530560 A JP 2018530560A JP 2018530560 A JP2018530560 A JP 2018530560A JP 2019510733 A5 JP2019510733 A5 JP 2019510733A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- acid sequence
- seq
- variable region
- chain variable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021049294A JP2021100957A (ja) | 2015-12-15 | 2021-03-23 | キメラ及びヒト化抗ヒトｃｔｌａ４モノクローナル抗体ならびにその使用 |
| JP2022096901A JP7286845B2 (ja) | 2015-12-15 | 2022-06-15 | キメラ及びヒト化抗ヒトｃｔｌａ４モノクローナル抗体ならびにその使用 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562267735P | 2015-12-15 | 2015-12-15 | |
| US62/267,735 | 2015-12-15 | ||
| US201662309169P | 2016-03-16 | 2016-03-16 | |
| US62/309,169 | 2016-03-16 | ||
| US201662359036P | 2016-07-06 | 2016-07-06 | |
| US62/359,036 | 2016-07-06 | ||
| PCT/US2016/066698 WO2017106372A1 (en) | 2015-12-15 | 2016-12-14 | Chimeric and humanized anti-human ctla4 monoclonal antibodies and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021049294A Division JP2021100957A (ja) | 2015-12-15 | 2021-03-23 | キメラ及びヒト化抗ヒトｃｔｌａ４モノクローナル抗体ならびにその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019510733A JP2019510733A (ja) | 2019-04-18 |
| JP2019510733A5 true JP2019510733A5 (enExample) | 2020-01-30 |
| JP6858779B2 JP6858779B2 (ja) | 2021-04-14 |
Family
ID=59057509
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018530560A Active JP6858779B2 (ja) | 2015-12-15 | 2016-12-14 | キメラ及びヒト化抗ヒトｃｔｌａ４モノクローナル抗体ならびにその使用 |
| JP2021049294A Pending JP2021100957A (ja) | 2015-12-15 | 2021-03-23 | キメラ及びヒト化抗ヒトｃｔｌａ４モノクローナル抗体ならびにその使用 |
| JP2022096901A Active JP7286845B2 (ja) | 2015-12-15 | 2022-06-15 | キメラ及びヒト化抗ヒトｃｔｌａ４モノクローナル抗体ならびにその使用 |
| JP2023085801A Active JP7790837B2 (ja) | 2015-12-15 | 2023-05-24 | キメラ及びヒト化抗ヒトｃｔｌａ４モノクローナル抗体ならびにその使用 |
| JP2025130097A Active JP7904374B2 (ja) | 2015-12-15 | 2025-08-04 | キメラ及びヒト化抗ヒトｃｔｌａ４モノクローナル抗体ならびにその使用 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021049294A Pending JP2021100957A (ja) | 2015-12-15 | 2021-03-23 | キメラ及びヒト化抗ヒトｃｔｌａ４モノクローナル抗体ならびにその使用 |
| JP2022096901A Active JP7286845B2 (ja) | 2015-12-15 | 2022-06-15 | キメラ及びヒト化抗ヒトｃｔｌａ４モノクローナル抗体ならびにその使用 |
| JP2023085801A Active JP7790837B2 (ja) | 2015-12-15 | 2023-05-24 | キメラ及びヒト化抗ヒトｃｔｌａ４モノクローナル抗体ならびにその使用 |
| JP2025130097A Active JP7904374B2 (ja) | 2015-12-15 | 2025-08-04 | キメラ及びヒト化抗ヒトｃｔｌａ４モノクローナル抗体ならびにその使用 |
Country Status (25)
| Country | Link |
|---|---|
| US (3) | US10618960B2 (enExample) |
| EP (2) | EP3389699B1 (enExample) |
| JP (5) | JP6858779B2 (enExample) |
| KR (2) | KR20250108763A (enExample) |
| CN (1) | CN108430499B (enExample) |
| AU (3) | AU2016370648B2 (enExample) |
| CA (1) | CA3006984C (enExample) |
| DK (1) | DK3389699T5 (enExample) |
| ES (1) | ES2979210T3 (enExample) |
| FI (1) | FI3389699T3 (enExample) |
| HR (1) | HRP20240719T1 (enExample) |
| HU (1) | HUE066907T2 (enExample) |
| IL (3) | IL259988B2 (enExample) |
| LT (1) | LT3389699T (enExample) |
| MX (3) | MX2018006925A (enExample) |
| MY (1) | MY186974A (enExample) |
| PL (1) | PL3389699T3 (enExample) |
| PT (1) | PT3389699T (enExample) |
| RS (1) | RS65703B1 (enExample) |
| SG (1) | SG11201804969PA (enExample) |
| SI (1) | SI3389699T1 (enExample) |
| SM (1) | SMT202400211T1 (enExample) |
| TW (1) | TWI739781B (enExample) |
| WO (1) | WO2017106372A1 (enExample) |
| ZA (1) | ZA201804077B (enExample) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3303394T3 (da) | 2015-05-29 | 2020-07-06 | Agenus Inc | Anti-ctla-4-antistoffer og fremgangsmåder til anvendelse deraf |
| EP3515489B1 (en) | 2016-09-19 | 2025-11-05 | OncoC4, Inc. | Cd80 and cd86 binding protein compositions and uses thereof |
| IL307242B1 (en) | 2016-12-07 | 2026-07-01 | Agenus Inc | Anti-CTLA-4 antibodies and methods of using them |
| CN111511762B (zh) | 2017-08-21 | 2025-05-06 | 天演药业公司 | 抗cd137分子及其用途 |
| AU2018366199A1 (en) * | 2017-11-08 | 2020-05-28 | Xencor, Inc. | Bispecific and monospecific antibodies using novel anti-PD-1 sequences |
| WO2019148444A1 (en) | 2018-02-02 | 2019-08-08 | Adagene Inc. | Anti-ctla4 antibodies and methods of making and using the same |
| KR102834864B1 (ko) * | 2018-02-02 | 2025-07-16 | 온코씨4, 아이앤씨. | 개선된 면역치료 효과를 갖지만 약화된 부작용을 갖는 돌연변이 항-ctla-4 항체 |
| SG11202007018QA (en) * | 2018-02-02 | 2020-08-28 | Oncoimmune Inc | Methods of selecting and designing safer and more effective anti-ctla-4 antibodies for cancer therapy |
| WO2019148445A1 (en) | 2018-02-02 | 2019-08-08 | Adagene Inc. | Precision/context-dependent activatable antibodies, and methods of making and using the same |
| WO2019233413A1 (en) * | 2018-06-05 | 2019-12-12 | Jiangsu Alphamab Biopharmaceuticals Co., Ltd. | Dimer and use thereof |
| EP3617230A1 (en) * | 2018-09-03 | 2020-03-04 | BioInvent International AB | Novel antibodies and nucleotide sequences, and uses thereof |
| WO2020127377A1 (en) | 2018-12-21 | 2020-06-25 | Ose Immunotherapeutics | Bifunctional anti-pd-1/il-7 molecule |
| CN114008071B (zh) | 2018-12-27 | 2025-01-21 | 吉加根公司 | 抗ctla-4结合蛋白及其使用方法 |
| WO2020165374A1 (en) | 2019-02-14 | 2020-08-20 | Ose Immunotherapeutics | Bifunctional molecule comprising il-15ra |
| TW202136287A (zh) | 2019-12-17 | 2021-10-01 | 法商Ｏｓｅ免疫治療公司 | 包含il-7變體之雙官能分子 |
| US12559565B2 (en) | 2020-04-13 | 2026-02-24 | Biosion Inc. | Antibodies binding CTLA4 and uses thereof |
| AU2021262609A1 (en) | 2020-05-01 | 2022-12-22 | Kashiv Biosciences, Llc | An improved process of purification of protein |
| WO2022112198A1 (en) | 2020-11-24 | 2022-06-02 | Worldwide Innovative Network | Method to select the optimal immune checkpoint therapies |
| JP2024508207A (ja) | 2020-12-02 | 2024-02-26 | ブイアイビー ブイゼットダブリュ | がんに対する組み合わせ治療におけるｌｔｂｒアゴニスト |
| WO2022169269A1 (ko) * | 2021-02-03 | 2022-08-11 | 주식회사 유틸렉스 | 항 ctla-4 항체 및 이의 용도 |
| EP4320156A1 (en) | 2021-04-09 | 2024-02-14 | Ose Immunotherapeutics | Scaffold for bifunctioanl molecules comprising pd-1 or cd28 and sirp binding domains |
| MX2023011964A (es) | 2021-04-09 | 2024-01-08 | Ose Immunotherapeutics | Nuevo andamio para moléculas bifuncionales con propiedades mejoradas. |
| JP7345889B2 (ja) * | 2021-06-17 | 2023-09-19 | 株式会社ニューギン | 遊技機 |
| AU2022361768A1 (en) * | 2021-10-08 | 2024-05-02 | Kashiv Biosciences, Llc | Separation of pre-peak and post-peak in fusion protein sample by using size exclusion high performance liquid chromatography |
| WO2023057994A1 (en) * | 2021-10-08 | 2023-04-13 | Kashiv Biosciences, Llc | Separation of pre-peak in fusion protein sample by using size exclusion high performance liquid chromatography |
| MX2024004429A (es) | 2021-10-29 | 2024-05-06 | Oncoc4 Inc | Regimenes de dosificacion del anticuerpo anti-ctla-4. |
| US20260035484A1 (en) * | 2021-10-29 | 2026-02-05 | Longbio Pharma (Suzhou) Co., Ltd. | Isolated antigen binding protein and use thereof |
| WO2024003360A1 (en) | 2022-07-01 | 2024-01-04 | Institut Curie | Biomarkers and uses thereof for the treatment of neuroblastoma |
| EP4565610A1 (en) | 2022-08-02 | 2025-06-11 | Ose Immunotherapeutics | Multifunctional molecule directed against cd28 |
| JP2025531229A (ja) | 2022-09-16 | 2025-09-19 | オンコシーフォー、インク． | 腺様嚢胞がんを処置するための抗ｃｔｌａ－４抗体の使用 |
| WO2024194605A1 (en) | 2023-03-17 | 2024-09-26 | Quell Therapeutics Limited | Treg therapy |
| JP2026512425A (ja) | 2023-03-30 | 2026-04-16 | オーエスイー・イミュノセラピューティクス | 免疫細胞増強分子の発現のための活性化免疫細胞に標的化された脂質ベースのナノ粒子及びその使用 |
| WO2024200820A1 (en) | 2023-03-30 | 2024-10-03 | Ose Immunotherapeutics | Method of synthesis of targeted lipid nanoparticle and uses thereof |
| KR20260005250A (ko) | 2023-04-28 | 2026-01-09 | 온코씨4, 아이앤씨. | 항-ctla-4 항체와 항-pd-1 항체의 조합 및 이의 치료적 용도 |
| EP4724498A2 (en) * | 2023-06-09 | 2026-04-15 | The Regents of the University of California | Methods for identifying and correcting tumor humoral immune dysfunction |
| AU2024402568A1 (en) | 2023-12-22 | 2026-07-09 | BioNTech SE | Anti-ctla-4 antibody for treatment of patients with prostate cancer and combination therapy with a radioligand therapeutic agent |
| WO2025201659A1 (en) | 2024-03-28 | 2025-10-02 | BioNTech SE | Combination therapy comprising therapeutic rna cancer vaccines and anti-ctla4 antibodies for cancer treatment |
| JPWO2025234450A1 (enExample) * | 2024-05-08 | 2025-11-13 | ||
| WO2025242835A1 (en) | 2024-05-22 | 2025-11-27 | Ose Immunotherapeutics | Molecules comprising masking linkers and uses thereof for the treatment of cancer |
| WO2026041780A2 (en) | 2024-08-23 | 2026-02-26 | BioNTech SE | Combination therapy comprising anti-ctla4 antibodies and chemotherapy for cancer treatment |
| WO2026057739A1 (en) | 2024-09-12 | 2026-03-19 | BioNTech SE | Combination therapy comprising anti-ctla4 antibodies and anti-pd-1 antibodies for platinum-resistant ovarian cancer treatment |
| WO2026068705A1 (en) | 2024-09-26 | 2026-04-02 | Ose Immunotherapeutics | Lipid-based nanoparticles comprising non-glycosylated fc domains and uses thereof |
| WO2026125485A1 (en) | 2024-12-11 | 2026-06-18 | BioNTech SE | Anti-ctla4 antibodies for treating non-small cell lung cancer |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
| ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| MXPA02001878A (es) | 1999-08-23 | 2003-08-20 | Dana Farber Cancer Inst Inc | Moleculas b7-4 novedosas y usos de las mismas. |
| ES2539411T3 (es) | 1999-08-23 | 2015-06-30 | Dana-Farber Cancer Institute, Inc. | PD-1, receptor para la B7-4 y su utilización |
| US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| CA3016482A1 (en) | 1999-11-30 | 2001-06-07 | Mayo Foundation For Medical Education And Research | B7-h1, a novel immunoregulatory molecule |
| US6803192B1 (en) | 1999-11-30 | 2004-10-12 | Mayo Foundation For Medical Education And Research | B7-H1, a novel immunoregulatory molecule |
| AU2001233027A1 (en) * | 2000-01-27 | 2001-08-07 | Genetics Institute, Llc | Antibodies against ctla4 (cd152), conjugates comprising same, and uses thereof |
| US7794710B2 (en) | 2001-04-20 | 2010-09-14 | Mayo Foundation For Medical Education And Research | Methods of enhancing T cell responsiveness |
| EP1456652A4 (en) | 2001-11-13 | 2005-11-02 | Dana Farber Cancer Inst Inc | IMMUNOCELL ACTIVATION MODULATING SUBSTANCES AND USE METHOD THEREFOR |
| ES2367430T3 (es) | 2002-12-23 | 2011-11-03 | Wyeth Llc | Anticuerpos contra pd-1 y sus usos. |
| WO2006029219A2 (en) * | 2004-09-08 | 2006-03-16 | Ohio State University Research Foundation | Human monoclonal anti-ctla4 antibodies in cancer treatment |
| EP1793857A4 (en) * | 2004-09-08 | 2008-09-03 | Univ Ohio State Res Found | COMBINED THERAPY USING ANTI-CTLA4 ANTI-4-1BB ANTIBODIES |
| SG156643A1 (en) | 2004-10-15 | 2009-11-26 | Verisign Inc | One time password |
| CA2591914C (en) | 2005-01-24 | 2017-04-25 | Board Of Regents, The University Of Texas System | Fc-fusion constructs binding to phosphatidylserine and their therapeutic use |
| EP3530736A3 (en) * | 2005-05-09 | 2019-11-06 | ONO Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
| KR101704734B1 (ko) | 2005-07-01 | 2017-02-09 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체 |
| US8062852B2 (en) | 2007-10-01 | 2011-11-22 | The Children's Hospital And Regional Medical Center | Detection and treatment of autoimmune disorders |
| CN101628940B (zh) * | 2008-07-15 | 2011-11-23 | 中国科学院生物物理研究所 | 一种单克隆抗体及其应用 |
| GB0903325D0 (en) * | 2009-02-26 | 2009-04-08 | Univ Aberdeen | Antibody molecules |
| GB201103955D0 (en) * | 2011-03-09 | 2011-04-20 | Antitope Ltd | Antibodies |
| US20150079100A1 (en) * | 2012-03-23 | 2015-03-19 | Bristol-Myers Squibb Company | Methods of treatments using ctla-4 antibodies |
| SMT201900242T1 (it) * | 2012-12-03 | 2019-05-10 | Bristol Myers Squibb Co | Incremento dell'attivita' anti-cancro di proteine di fuzione a fc immunomodulatrici |
| WO2014209804A1 (en) * | 2013-06-24 | 2014-12-31 | Biomed Valley Discoveries, Inc. | Bispecific antibodies |
| CN104292334B (zh) * | 2014-04-25 | 2018-11-27 | 河南省健康伟业生物医药研究股份有限公司 | 一种全人源抗ctla-4单克隆抗体、制备方法及应用 |
| EP3515489B1 (en) | 2016-09-19 | 2025-11-05 | OncoC4, Inc. | Cd80 and cd86 binding protein compositions and uses thereof |
-
2016
- 2016-12-14 AU AU2016370648A patent/AU2016370648B2/en active Active
- 2016-12-14 HU HUE16876612A patent/HUE066907T2/hu unknown
- 2016-12-14 SG SG11201804969PA patent/SG11201804969PA/en unknown
- 2016-12-14 EP EP16876612.9A patent/EP3389699B1/en active Active
- 2016-12-14 CA CA3006984A patent/CA3006984C/en active Active
- 2016-12-14 RS RS20240735A patent/RS65703B1/sr unknown
- 2016-12-14 DK DK16876612.9T patent/DK3389699T5/da active
- 2016-12-14 EP EP24164173.7A patent/EP4374926A3/en active Pending
- 2016-12-14 CN CN201680073425.2A patent/CN108430499B/zh active Active
- 2016-12-14 HR HRP20240719TT patent/HRP20240719T1/hr unknown
- 2016-12-14 SM SM20240211T patent/SMT202400211T1/it unknown
- 2016-12-14 PL PL16876612.9T patent/PL3389699T3/pl unknown
- 2016-12-14 FI FIEP16876612.9T patent/FI3389699T3/fi active
- 2016-12-14 ES ES16876612T patent/ES2979210T3/es active Active
- 2016-12-14 MY MYPI2018000904A patent/MY186974A/en unknown
- 2016-12-14 US US16/062,350 patent/US10618960B2/en active Active
- 2016-12-14 IL IL259988A patent/IL259988B2/en unknown
- 2016-12-14 KR KR1020257022200A patent/KR20250108763A/ko active Pending
- 2016-12-14 WO PCT/US2016/066698 patent/WO2017106372A1/en not_active Ceased
- 2016-12-14 PT PT168766129T patent/PT3389699T/pt unknown
- 2016-12-14 IL IL296354A patent/IL296354B2/en unknown
- 2016-12-14 JP JP2018530560A patent/JP6858779B2/ja active Active
- 2016-12-14 IL IL310404A patent/IL310404A/en unknown
- 2016-12-14 MX MX2018006925A patent/MX2018006925A/es unknown
- 2016-12-14 SI SI201631826T patent/SI3389699T1/sl unknown
- 2016-12-14 KR KR1020187017368A patent/KR102830926B1/ko active Active
- 2016-12-14 LT LTEPPCT/US2016/066698T patent/LT3389699T/lt unknown
- 2016-12-15 TW TW105141656A patent/TWI739781B/zh active
-
2018
- 2018-06-07 MX MX2025001302A patent/MX2025001302A/es unknown
- 2018-06-07 MX MX2025001300A patent/MX2025001300A/es unknown
- 2018-06-18 ZA ZA2018/04077A patent/ZA201804077B/en unknown
-
2020
- 2020-02-27 US US16/803,972 patent/US11629188B2/en active Active
-
2021
- 2021-03-23 JP JP2021049294A patent/JP2021100957A/ja active Pending
-
2022
- 2022-06-15 JP JP2022096901A patent/JP7286845B2/ja active Active
-
2023
- 2023-03-22 US US18/188,098 patent/US12473362B2/en active Active
- 2023-05-19 AU AU2023203169A patent/AU2023203169B2/en active Active
- 2023-05-24 JP JP2023085801A patent/JP7790837B2/ja active Active
-
2025
- 2025-08-04 JP JP2025130097A patent/JP7904374B2/ja active Active
-
2026
- 2026-02-05 AU AU2026200849A patent/AU2026200849A1/en active Pending